3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings, in CNY as reported — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | CN¥400M | -CN¥131M | 13.1% | -29.7% | 28.8% | -121.7% | -CN¥149M | CN¥135M | CN¥10M |
| 2024 | CN¥343M | -CN¥37M | 13.9% | -7.5% | 1.7% | -80.8% | -CN¥16M | — | CN¥8M |
| 2023 | CN¥305M | -CN¥37M | 12.7% | -7.3% | — | — | -CN¥46M | — | CN¥7M |
Over the past 2 years, POMDOCTOR Ltd's revenue has grown 14.5% per year. These are computed facts, not advice.
As of FY2025, POMDOCTOR Ltd reported CN¥135M of total debt against CN¥10M of cash.
In FY2025, gross margin was 13.1%, operating margin -29.7%, and net margin -32.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — its annual and interim reports, in CNY as reported (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (annual and interim filings, reported in CNY) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.